Slide Show: Melanoma and Other Skin Cancers

Investigators of the phase 3 C-POST trial will continue to follow up with patients and assess the key secondary end point of overall survival.

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Phase 3 data may support the photodynamic therapy as a noninvasive treatment option for patients with superficial basal cell carcinoma.

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.